Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.8 (
polynucleotide phosphorylase
)
723
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nuclear existence of epidermal growth factor receptor (EGFR) has been documented for more than two decades. Resistance of cancer to radiotherapy is frequently correlated with elevated EGFR expression, activity, and nuclear translocation. However, the role of nuclear EGFR (nEGFR) in radioresistance of cancers remains elusive. In the current study, we identified a novel nEGFR-associated protein,
polynucleotide phosphorylase
(
PNPase
), which possesses 3' to 5' exoribonuclease activity toward
c-MYC
mRNA. Knockdown of
PNPase
increased radioresistance. Inactivation or knock-down of EGFR enhanced
PNPase
-mediated
c-MYC
mRNA degradation in breast cancer cells, and also increased its radiosensitivity. Interestingly, the association of nEGFR with
PNPase
and DNA-dependent protein kinase (DNAPK) increased significantly in breast cancer cells after exposure to ionizing radiation (IR). We also demonstrated that DNAPK phosphorylates
PNPase
at Ser-776, which is critical for its ribonuclease activity. The phospho-mimetic S776D mutant of
PNPase
impaired its ribonuclease activity whereas the nonphosphorylatable S776A mutant effectively degraded
c-MYC
mRNA. Here, we uncovered a novel role of nEGFR in radioresistance, and that is, upon ionizing radiation, nEGFR inactivates the ribonuclease activity of
PNPase
toward
c-MYC
mRNA through DNAPK-mediated Ser-776 phosphorylation, leading to increase of
c-MYC
mRNA, which contributes to radioresistance of cancer cells.
...
PMID:Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. 2281 74